Amylyx Pharmaceuticals, Inc.
About Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $0
- Net income
- -$144.7M
- Total assets
- $332.6M
- Market cap
- $1.5B
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Cost of revenue
- $0
- Operating income
- -$153.3M
- Income tax
- $46.0K
- Net income
- -$144.7M
- EPS (basic)
- $-1.53
- EPS (diluted)
- $-1.53
Balance sheet
- Total assets
- $332.6M
- Current assets
- $323.7M
- Total liabilities
- $27.4M
- Current liabilities
- $22.7M
- Shareholders’ equity
- $305.3M
Cash flow
- Operating cash flow
- -$123.3M
- Investing cash flow
- $14.0M
- Financing cash flow
- $257.0M
- Net cash flow
- $148.8M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.5B
- EPS (diluted)
- $-1.53
- Dividend yield
- 12.9%
- Shares outstanding
- 113.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jan 7, 2022
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $144.7M in FY2025.
- Trading 29% below its 52-week high.
- Pays a dividend yielding about 12.9% annually.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Amylyx Pharmaceuticals, Inc..
Write a review
News about Amylyx Pharmaceuticals, Inc.
News & sentiment via Polygon.io
